Please login to the form below

Not currently logged in
Email:
Password:

Parsabiv

This page shows the latest Parsabiv news and features for those working in and with pharma, biotech and healthcare.

NICE set to back Parsabiv for kidney disease complication

NICE set to back Parsabiv for kidney disease complication

NICE set to back Parsabiv for kidney disease complication. Draft guidance recommends Amgen treatment for secondary hyperparathyroidism. ... Parsabiv was approved by the EMA last November and according to the company has advantages over its older drug.

Latest news

  • Amgen's chronic kidney disease drug Parsabiv cleared in US Amgen's chronic kidney disease drug Parsabiv cleared in US

    Amgen's chronic kidney disease drug Parsabiv cleared in US. Sensipar follow-up is the first therapy to be approved for treatment of sHPT in 12 years. ... to be used in clinical practice, the monthly costs of Parsabiv and Sensipar should be comparable.".

  • Amgen wins European approval for Parsabiv Amgen wins European approval for Parsabiv

    Amgen wins European approval for Parsabiv. Follows FDA knock-back in August for the chronic kidney disease treatment. ... In contrast, Parsabiv is administered as an infusion during dialysis, side-stepping the compliance issue.

  • FDA knocks back Amgen's chronic kidney disease treatment FDA knocks back Amgen's chronic kidney disease treatment

    FDA knocks back Amgen's chronic kidney disease treatment. Parsabiv was hoped to equal or exceed solid earner Sensipar. ... In contrast, Parsabiv is administered as an infusion during dialysis, side-stepping the compliance issue.

More from news
Approximately 4 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics